Treatment of disease via transcription factor modulation

Abstract

Disclosed herein are methods of treatment of various disease states in which an individual in need thereof if administered one or more therapeutic agents capable of modulating one or more transcription factors. Also disclosed are methods by which an individual may be treated for one or more disease states, in which loci in which transcription factors bind are detected.

What is claimed is: 
     
         1 . A method of treating a disease with a therapeutic agent, in an individual in need thereof. 
     
     
         2 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 1, wherein said therapeutic agent is selected from an agent listed in column C of Table 1, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor ESR1. 
     
     
         3 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 2, wherein said therapeutic agent is selected from an agent listed in column C of Table 2, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor ESR2. 
     
     
         4 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 3, wherein said therapeutic agent is selected from an agent listed in column C of Table 3, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor AR. 
     
     
         5 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 4, wherein said therapeutic agent is selected from an agent listed in column C of Table 4, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor PGR. 
     
     
         6 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 5, wherein said therapeutic agent is selected from an agent listed in column C of Table 5, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HDAC2. 
     
     
         7 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 6, wherein said therapeutic agent is selected from an agent listed in column C of Table 6, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NR3C1. 
     
     
         8 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 7, wherein said therapeutic agent is selected from an agent listed in column C of Table 7, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor VDR. 
     
     
         9 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 8, wherein said therapeutic agent is selected from an agent listed in column C of Table 8, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor RXRA. 
     
     
         10 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 9, wherein said therapeutic agent is selected from an agent listed in column C of Table 9, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor RARG. 
     
     
         11 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 10, wherein said therapeutic agent is selected from an agent listed in column C of Table 10, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NFKB1. 
     
     
         12 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 11, wherein said therapeutic agent is selected from an agent listed in column C of Table 11, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor CHD1. 
     
     
         13 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 12, wherein said therapeutic agent is selected from an agent listed in column C of Table 12, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NOTCH1. 
     
     
         14 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 13, wherein said therapeutic agent is selected from an agent listed in column C of Table 13, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor STAT5B. 
     
     
         15 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 14, wherein said therapeutic agent is selected from an agent listed in column C of Table 14, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HDAC1. 
     
     
         16 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 15, wherein said therapeutic agent is selected from an agent listed in column C of Table 15, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor CDK9. 
     
     
         17 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 16, wherein said therapeutic agent is selected from an agent listed in column C of Table 16, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HDAC6. 
     
     
         18 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 17, wherein said therapeutic agent is selected from an agent listed in column C of Table 17, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor JUN. 
     
     
         19 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 18, wherein said therapeutic agent is selected from an agent listed in column C of Table 18, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HDAC8. 
     
     
         20 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 19, wherein said therapeutic agent is selected from an agent listed in column C of Table 19, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor EP300. 
     
     
         21 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 20, wherein said therapeutic agent is selected from an agent listed in column C of Table 20, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor MYC. 
     
     
         22 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 21, wherein said therapeutic agent is selected from an agent listed in column C of Table 21, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor BRD4. 
     
     
         23 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 22, wherein said therapeutic agent is selected from an agent listed in column C of Table 22, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NFATC1. 
     
     
         24 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 23, wherein said therapeutic agent is selected from an agent listed in column C of Table 23, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor RUNX1. 
     
     
         25 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 24, wherein said therapeutic agent is selected from an agent listed in column C of Table 24, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor TCF7L2. 
     
     
         26 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 25, wherein said therapeutic agent is selected from an agent listed in column C of Table 25, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor PHF8. 
     
     
         27 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 26, wherein said therapeutic agent is selected from an agent listed in column C of Table 26, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HNF4A. 
     
     
         28 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 27, wherein said therapeutic agent is selected from an agent listed in column C of Table 27, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor MED1. 
     
     
         29 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 28, wherein said therapeutic agent is selected from an agent listed in column C of Table 28, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NFKB2. 
     
     
         30 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 29, wherein said therapeutic agent is selected from an agent listed in column C of Table 29, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor CREBBP. 
     
     
         31 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 30, wherein said therapeutic agent is selected from an agent listed in column C of Table 30, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor STAT3. 
     
     
         32 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 31, wherein said therapeutic agent is selected from an agent listed in column C of Table 31, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor SMARCA4. 
     
     
         33 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 32, wherein said therapeutic agent is selected from an agent listed in column C of Table 32, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor BRD2. 
     
     
         34 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 33, wherein said therapeutic agent is selected from an agent listed in column C of Table 33, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor STAT4. 
     
     
         35 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 34, wherein said therapeutic agent is selected from an agent listed in column C of Table 34 and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor KDM5B. 
     
     
         36 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 35, wherein said therapeutic agent is selected from an agent listed in column C of Table 35, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor BRD3. 
     
     
         37 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 36, wherein said therapeutic agent is selected from an agent listed in column C of Table 36, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor EZH2. 
     
     
         38 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 37, wherein said therapeutic agent is selected from an agent listed in column C of Table 37, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor ATF1. 
     
     
         39 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 38, wherein said therapeutic agent is selected from an agent listed in column C of Table 38, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor CREB1. 
     
     
         40 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 39, wherein said therapeutic agent is selected from an agent listed in column C of Table 39, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor TP53. 
     
     
         41 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 40, wherein said therapeutic agent is selected from an agent listed in column C of Table 40, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor HNF4G. 
     
     
         42 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 41, wherein said therapeutic agent is selected from an agent listed in column C of Table 41, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NR2C2. 
     
     
         43 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 42, wherein said therapeutic agent is selected from an agent listed in column C of Table 42, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor SIRT6. 
     
     
         44 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 43, wherein said therapeutic agent is selected from an agent listed in column C of Table 43 and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor BRCA1. 
     
     
         45 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 44, wherein said therapeutic agent is selected from an agent listed in column C of Table 44, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor NR1H2. 
     
     
         46 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 45, wherein said therapeutic agent is selected from an agent listed in column C of Table 45, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor KAT5. 
     
     
         47 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 46, wherein said therapeutic agent is selected from an agent listed in column C of Table 46 and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor CTNNB1. 
     
     
         48 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 47, wherein said therapeutic agent is selected from an agent listed in column C of Table 47, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor KDM5A. 
     
     
         49 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 48, wherein said therapeutic agent is selected from an agent listed in column C of Table 48, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor PPARG. 
     
     
         50 . The method of  claim 1 , wherein said disease is selected from one or more diseases or conditions listed in column B of Table 49, wherein said therapeutic agent is selected from an agent listed in column C of Table 49, and wherein said therapeutic agent is administered in an amount effective to modulate the transcription factor ZEB1. 
     
     
         51 . A method of treating a disease comprising the step of identifying one or more, or two or more, or three or more, or four or more, or five or more, or six or more, or seven or more, or eight or more, or nine or more, or ten or more, or 11 or more, or 12 or more, or 13 or more, or 14 or more, or 15 or more, or 16 or more, or 17 or more, or 18 or more, or 19 or more, or 20 or more, or 21 or more, or 22 or more, or 23 or more, or 24 or more, or 25 or more, or 26 or more, or 27 or more, or 28 or more, or 29 or more, or 30 or more, or 31 or more, or 32 or more, or 33 or more, or 34 or more, or 35 or more, or 36 or more, or 37 or more, or 38 or more, or 39 or more, or 40 or more, or more than 40 loci associated with said disease in an individual suspected of having or having said disease, and treating said individual with a compound that modulates a TF associated with said one or more loci.